a public good project by the
Synthesis
Company
of California

© 2026

Evgeny Kiselev | doi.page

0 works0 citations0 h-index

Evgeny Kiselev

National Institutes of Health(US)National Cancer Institute(US)Center for Cancer Research(US)Voronezh State University(RU)

Publications by Year

Research Areas

Cancer therapeutics and mechanisms, Adenosine and Purinergic Signaling, Synthesis and Biological Evaluation, Receptor Mechanisms and Signaling, Synthesis and biological activity

Most-Cited Works

→ Structure of the human P2Y12 receptor in complex with an antithrombotic drug(2014)392 cited
→ Two disparate ligand-binding sites in the human P2Y1 receptor(2015)367 cited
→ Nucleotides Acting at P2Y Receptors: Connecting Structure and Function(2015)101 cited
→ Renal Intercalated Cells Sense and Mediate Inflammation via the P2Y14 Receptor(2015)85 cited
→ Design, Synthesis, and Evaluation of Dibenzo[c,h][1,6]naphthyridines as Topoisomerase I Inhibitors and Potential Anticancer Agents(2010)75 cited
→ 7-Azaindenoisoquinolines as Topoisomerase I Inhibitors and Potential Anticancer Agents(2011)61 cited

→ Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y₁₄ Receptor Antagonists(2016)

52 cited

→ Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl–DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl–DNA Phosphodiesterase 2 (Tdp2)(2017)51 cited

→ Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents(2018)50 cited

→ Optimization of the Lactam Side Chain of 7-Azaindenoisoquinoline Topoisomerase I Inhibitors and Mechanism of Action Studies in Cancer Cells(2014)46 cited